NeuroCycle Therapeutics Awarded NIH SBIR Grant to Study Next-Generation Treatment of Dravet Syndrome

March 1, 2019

NeuroCycle Therapeutics, Inc. announced it had been awarded a $0.5M Small Business Innovation Research grant from the National institute of Neurological Disorders and Stroke (NINDS) to evaluate its advanced subtype-selective GABAA receptor modulators, NCT10004 and NCT10015, in models of Dravet Syndrome (Award Number R43NS107051).

This grant builds upon the company’s strategy to develop a portfolio of small molecule drug candidates that maximize efficacy and minimize side effects through selective targeting of the central nervous system.